Table 3.
Hypofractionated radiotherapy including pelvic nodes
| Reference | Study design | Number of patients | Fractionation (total dose/singel dose/fractions) | pelvic RT dose schema | EQD for tumor α/β-ratio 1.4Gy | EQD for normal tissue α/β-ratio 3Gy | Follow-up | Acute GU toxicitiy | Late GU toxicity | Acute GI toxicity | Late GI toxicity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| McDonald, A.M. [31] | Retrospective | 57 PORT and 31 WPRT | 70Gy/2.5Gy/28 fractions | 50.4Gy/1.8Gy/28 fractions | 80.3Gy | 77Gy | 41 months | 18/31(58%) in PORT, 28/57(49%) in WPRT ≥2° | 4/57(7%)in WPRT, 0% in PORT ≥ III° | 7/31(23%) in PORT, 23/57 (40%) in WPRT ≥ II° | 0% in PORT, 10/57(18%) in WPRT ≥ II° |
| McCammon, R. [30] | Retrospective | 30 | 70Gy/2.5Gy/28 fractions | 50.4Gy/1.8Gy/28 fractions | 80.3Gy | 77Gy | 24 months | 36.7% ≥2° | 10% ≥ II° | 20% | 13% ≥ II° |
| Adkinson, J.B. [29] | Phase I prospective | 53 | 70Gy/2.5Gy/28 fractions | 56Gy/2Gy/28 fractions | 80.3Gy | 77Gy | 25.4 months | 20/53(38%) ≥2° | 14/53(27%) ≥ II° | 17/53(32%) ≥ II° | 4/53(8%) ≥ II° |
| Pervez, N. [32] | Phase II prospective | 60 high-risk | 68Gy/2.72Gy/25 fractions | 45Gy/1.8Gy/25 fractions | 82.4Gy | 77.8Gy | 3 months | 34(40%) ≥ II° | - | 21(35%) ≥ II° | - |
| Quon, H. [33] | Prospective phase I-II | 97 pat. High-risk | 67.5Gy/2.7Gy/25 fractions | 45Gy/1.8Gy/25 fractions | 81.4Gy | 77Gy | 39 months median | 50% I°, 39% II°, 4% III° | 9% I°, 5% II°, 3% III°, 1% IV°. | 4% pat. 0°, 59% I°, 37% II° | 54% pat. 0°, 40% I°, 7% II° |
| Guckenberg, M. [34] | 150 consecutive patients | 109 PORT and 41 WPRT | 73,9Gy/2,31Gy/32 fx; 76.2Gy/2.31Gy/33 fx. | 45Gy/1.8Gy/25 fractions | 80.6Gy;83.1Gy. | 78.5Gy; 80.9Gy. | 50 months median | 85% pat. I°-II° | 22.4% Pat. ≥ II° at 60 months; less than 5% pat. III°. | - | 2 pat. ≥III° |
| Fonteyne, V. [53] | Prospective phase I | 31 patients | 69.3/2.77Gy/25 fractions | 50Gy/2.0Gy/25 fractions | 85Gy | 80Gy | 3 months median | 14/31 (45%) II°, 3/31 (9.7%) III° | - | 14/31 (45%) II° lower GI toxicity | - |
| Zilli, T. [54] | Prospective trial | 78 pat. | 50.4Gy/1.8Gy/28 fractions +6x4Gy boost (twice weekly) | 50.4Gy/1.8Gy/28 fractions | 85.2Gy with 1.5Gy alpha/beta | - | 57 months | ~1% = III° | 5 year suivival rate without II° GU toxicity 79.1 ± 4.8% | ~1% = III° | 5 year suivival rate without II° GI toxicity 84.1 ± 4.5% |